Drug-induced cognition disorders in the elderly: incidence, prevention and management - PubMed (original) (raw)

Review

Drug-induced cognition disorders in the elderly: incidence, prevention and management

S L Gray et al. Drug Saf. 1999 Aug.

Abstract

The aetiology of cognitive impairment is multifactorial; however, drugs are an important cause of delirium and dementia. Several factors may increase the risk of drug-induced cognition disorders in the elderly including imbalances in neurotransmitters (e.g. acetylcholine), age-related alterations in pharmacokinetics and pharmacodynamics, and high levels of medication use. Nearly any drug can cause cognitive impairment in susceptible individuals; however, certain classes are more commonly implicated. Benzodiazepines, opioids, anticholinergics, and tricyclic antidepressants are probably the worst offenders. Older antihypertensive agents (reserpine, clonidine) have negative effects on cognition; however, large clinical trials in the elderly indicate that commonly used agents [e.g. thiazide diuretics, calcium antagonists (amiodipine, diltiazem), ACE inhibitors (captopril, enalapril) and beta-blockers (atenolol)] have minimal effects on cognition. Newer antidepressants such as selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) and reversible inhibitors of monoamine oxidase A have not been shown to have negative effects on cognition. Although some drugs have shown low risk for causing cognition disorders in research studies, risk may be increased in frail older adults taking several medications and each case should be reviewed carefully. Identification of drug-induced cognitive impairment is crucial to early detection and resolution of symptoms. Preventive strategies directed at avoiding high risk medications when possible, appropriately adjusting doses based on age-related changes and close follow-up may prevent these conditions.

PubMed Disclaimer

Similar articles

• Drug-induced cognitive impairment in the elderly.
  Moore AR, O'Keeffe ST. Moore AR, et al. Drugs Aging. 1999 Jul;15(1):15-28. doi: 10.2165/00002512-199915010-00002. Drugs Aging. 1999. PMID: 10459729 Review.
• Identification and management of in-hospital drug-induced delirium in older patients.
  Catic AG. Catic AG. Drugs Aging. 2011 Sep 1;28(9):737-48. doi: 10.2165/11592240-000000000-00000. Drugs Aging. 2011. PMID: 21913739 Review.
• [Drug-induced Cognitive Impairment].
  Shinohara M, Yamada M. Shinohara M, et al. Brain Nerve. 2016 Apr;68(4):421-8. doi: 10.11477/mf.1416200415. Brain Nerve. 2016. PMID: 27056860 Review. Japanese.
• [Drug-induced cognitive impairment].
  Shinohara M, Yamada M. Shinohara M, et al. Brain Nerve. 2012 Dec;64(12):1405-10. Brain Nerve. 2012. PMID: 23209067 Review. Japanese.
• Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment.
  Poon IO. Poon IO. Pharmacotherapy. 2008 Mar;28(3):366-75. doi: 10.1592/phco.28.3.366. Pharmacotherapy. 2008. PMID: 18294116 Review.

Cited by

• Cohorts based on decade of death: no evidence for secular trends favoring later cohorts in cognitive aging and terminal decline in the AHEAD study.
  Hülür G, Infurna FJ, Ram N, Gerstorf D. Hülür G, et al. Psychol Aging. 2013 Mar;28(1):115-27. doi: 10.1037/a0029965. Epub 2012 Oct 8. Psychol Aging. 2013. PMID: 23046001 Free PMC article.
• Mild Cognitive Impairment in Young Type 1 Diabetes Mellitus Patients and Correlation with Diabetes Control, Lipid Profile, and High-sensitivity C-reactive Protein.
  Kumar N, Singh VB, Meena BL, Kumar D, Kumar H, Saini ML, Tiwari A. Kumar N, et al. Indian J Endocrinol Metab. 2018 Nov-Dec;22(6):780-784. doi: 10.4103/ijem.IJEM_58_18. Indian J Endocrinol Metab. 2018. PMID: 30766818 Free PMC article.
• Melatonin intervention to prevent delirium in hospitalized patients: A meta-analysis.
  You W, Fan XY, Lei C, Nie CC, Chen Y, Wang XL. You W, et al. World J Clin Cases. 2022 Apr 26;10(12):3773-3786. doi: 10.12998/wjcc.v10.i12.3773. World J Clin Cases. 2022. PMID: 35647160 Free PMC article.
• Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor.
  Liabeuf S, Pešić V, Spasovski G, Maciulaitis R, Bobot M, Farinha A, Wagner CA, Unwin RJ, Capasso G, Bumblyte IA, Hafez G; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Liabeuf S, et al. Clin Kidney J. 2023 Sep 18;16(12):2365-2377. doi: 10.1093/ckj/sfad241. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38045996 Free PMC article. Review.
• Mental disorders associated with benzodiazepine use among older primary care attenders--a regional survey.
  Balestrieri M, Marcon G, Samani F, Marini M, Sessa E, Gelatti U, Donato F. Balestrieri M, et al. Soc Psychiatry Psychiatr Epidemiol. 2005 Apr;40(4):308-15. doi: 10.1007/s00127-005-0899-9. Soc Psychiatry Psychiatr Epidemiol. 2005. PMID: 15834782

References

1. 1. Clin Cardiol. 1995 Jun;18(6):351-2 - PubMed
2. 1. Am J Psychiatry. 1992 Oct;149(10):1393-4 - PubMed
3. 1. Epilepsia. 1987;28 Suppl 3:S50-8 - PubMed
4. 1. J Clin Psychiatry. 1996;57 Suppl 1:7-11 - PubMed
5. 1. Arch Intern Med. 1986 Nov;146(11):2237-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal